AI-Powered Knowledge Engine

Ask anything about peptides, TRT, and optimizing your body

Get science-backed answers about peptides, hormones, and performance optimization — instantly.

Popular questions
Backed by science
Educational only
Not medical advice
Trending Now

Trending Articles

The latest research-backed articles on peptides and testosterone therapy from our library.

SELECT Trial: Semaglutide Reduces Heart Attack and Stroke Risk by 20%
Peptide15 min read

SELECT Trial: Semaglutide Reduces Heart Attack and Stroke Risk by 20%

The SELECT trial, published in the New England Journal of Medicine in 2023, was the largest cardiovascular outcomes trial ever conducted for a GLP-1 receptor agonist in patients without diabetes. With 17,604 participants followed for over 3 years, it demonstrated a 20% reduction in heart attacks, strokes, and cardiovascular death.

STEP 1 Trial: How Semaglutide 2.4mg Achieved 15% Weight Loss in Adults
Peptide14 min read

STEP 1 Trial: How Semaglutide 2.4mg Achieved 15% Weight Loss in Adults

The STEP 1 trial, published in the New England Journal of Medicine in 2021, was the landmark study that established semaglutide 2.4mg as the most effective anti-obesity medication available. With 1,961 participants achieving an average 14.9% body weight reduction over 68 weeks, the results fundamentally changed the obesity treatment landscape.

STEP 5 Trial: Two-Year Semaglutide Data Proves Long-Term Weight Loss Durability
Peptide13 min read

STEP 5 Trial: Two-Year Semaglutide Data Proves Long-Term Weight Loss Durability

The STEP 5 trial answered the critical question: does semaglutide maintain its weight loss effect over the long term? Published in Nature Medicine in 2022, this 104-week study showed that semaglutide 2.4mg sustained approximately 15% weight loss for two full years, with continued cardiometabolic benefits.

FLOW Trial: Semaglutide Protects Kidneys in Chronic Kidney Disease
Peptide14 min read

FLOW Trial: Semaglutide Protects Kidneys in Chronic Kidney Disease

The FLOW trial, published in the New England Journal of Medicine in 2024, was the first dedicated kidney outcomes trial for a GLP-1 receptor agonist. With 3,533 patients, it demonstrated that semaglutide reduced the risk of kidney disease progression by 24% — so effective that the trial was stopped early.

TRT and Cardiovascular Health: What the Research Actually Shows
TRT9 min read

TRT and Cardiovascular Health: What the Research Actually Shows

For years, the cardiovascular safety of testosterone replacement therapy (TRT) was a topic of intense debate. This article delves into the history of the controversy, the landmark TRAVERSE trial, and the current scientific consensus, providing a clear, evidence-based overview of what the research actually shows about TRT and heart health.

Testosterone and Body Composition: How TRT Affects Muscle, Fat, and Strength
TRT4 min read

Testosterone and Body Composition: How TRT Affects Muscle, Fat, and Strength

Research suggests that Testosterone Replacement Therapy (TRT) can significantly improve body composition by increasing lean muscle mass and reducing fat, particularly visceral fat. Studies, including the Bhasin dose-response trials, have demonstrated a clear link between testosterone levels and these positive changes, leading to enhanced strength and a more favorable metabolic profile.

What Is OnlinePeptideDoctor.com?

OnlinePeptideDoctor.com is an AI-powered knowledge engine built for researchers, biohackers, and health-conscious individuals who want science-backed information about peptides and testosterone replacement therapy.

45+

Peptides & compounds in our database

78+

Research-backed articles with PubMed citations

6

AI-powered tools for peptide research

How Peptide Research Works on OnlinePeptideDoctor.com

Simply type your question into the search bar above. Our AI analyzes clinical literature, PubMed studies, and expert protocols to deliver structured, evidence-based answers about any peptide or TRT topic — including mechanisms of action, dosing guidelines, benefits, risks, and who each compound is best suited for.